These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 37868479)

  • 1. Ring-Enhancing Progressive Multifocal Leukoencephalopathy Mimicking Glioma in a Presumed Immunocompetent Patient With a History of Multiple Sclerosis: A Case Report and Review of the Literature.
    Gonzalez SC; Nguyen A; Soto JM; Shan Y
    Cureus; 2023 Sep; 15(9):e45543. PubMed ID: 37868479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of demyelinating lesions in progressive multifocal leukoencephalopathy (PML): Comparison of magnetic resonance images and neuropathology of post-mortem brain.
    Ono D; Shishido-Hara Y; Mizutani S; Mori Y; Ichinose K; Watanabe M; Tanizawa T; Yokota T; Uchihara T; Fujigasaki H
    Neuropathology; 2019 Aug; 39(4):294-306. PubMed ID: 31155757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atypical Multiple Sclerosis Lesions or Progressive Multifocal Leukoencephalopathy Lesions: That Is the Question.
    De Mercanti SF; Gned D; Matta M; Iudicello M; Franchin E; Clerico M
    J Investig Med High Impact Case Rep; 2020; 8():2324709620939802. PubMed ID: 32646245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anaplastic astrocytoma mimicking progressive multifocal leucoencephalopathy: a case report and review of the overlapping syndromes.
    Kantorová E; Bittšanský M; Sivák Š; Baranovičová E; Hnilicová P; Nosáľ V; Čierny D; Zeleňák K; Brück W; Kurča E
    BMC Cancer; 2017 Jun; 17(1):424. PubMed ID: 28629398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natalizumab-associated progressive multifocal leukoencephalopathy (PML) in multiple sclerosis (MS): "a case report from Ireland with review of literature, clinical pitfalls and future direction".
    Mansoor S; Mullane G; Adenan MH; Kelly S; Water A; McPartland G; Murphy K
    Egypt J Neurol Psychiatr Neurosurg; 2021; 57(1):7. PubMed ID: 33437143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contrast-enhancing progressive multifocal leukoencephalopathy: radiological and pathological correlations: case report.
    Woo HH; Rezai AR; Knopp EA; Weiner HL; Miller DC; Kelly PJ
    Neurosurgery; 1996 Nov; 39(5):1031-4; discussion 1034-5. PubMed ID: 8905761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Probable progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome with immunosuppressant dose reduction following lung transplantation: a case report and literature review.
    Ishii K; Yamamoto F; Homma S; Okada Y; Nakamichi K; Saijo M; Tamaoka A
    BMC Neurol; 2019 Oct; 19(1):263. PubMed ID: 31672142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TSPO PET imaging of natalizumab-associated progressive multifocal leukoencephalopathy.
    Mahler C; Schumacher AM; Unterrainer M; Kaiser L; Höllbacher T; Lindner S; Havla J; Ertl-Wagner B; Patzig M; Seelos K; Neitzel J; Mäurer M; Krumbholz M; Metz I; Brück W; Stadelmann C; Merkler D; Gass A; Milenkovic V; Bartenstein P; Albert NL; Kümpfel T; Kerschensteiner M
    Brain; 2021 Oct; 144(9):2683-2695. PubMed ID: 33757118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progressive multifocal leukoencephalopathy and sphingosine 1-phosphate receptor modulators used in multiple sclerosis: an updated review of literature.
    Sriwastava S; Chaudhary D; Srivastava S; Beard K; Bai X; Wen S; Khalid SH; Lisak RP
    J Neurol; 2022 Mar; 269(3):1678-1687. PubMed ID: 34800168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progressive multifocal leukoencephalopathy in dimethyl fumarate-treated multiple sclerosis patients.
    Jordan AL; Yang J; Fisher CJ; Racke MK; Mao-Draayer Y
    Mult Scler; 2022 Jan; 28(1):7-15. PubMed ID: 32808554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progressive multifocal leukoencephalopathy in an immunocompetent patient: A case report and review of literature.
    Sriwastava S; Khan E; Khalid SH; Kaur A; Feizi P
    J Med Virol; 2022 Jun; 94(6):2860-2869. PubMed ID: 34854099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progressive multifocal leukoencephalopathy in a patient without apparent immunosuppression.
    Grewal J; Dalal P; Bowman M; Kaya B; Otero JJ; Imitola J
    J Neurovirol; 2016 Oct; 22(5):683-687. PubMed ID: 27273076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progressive multifocal leukoencephalopathy and relapsing-remitting multiple sclerosis: a comparative study.
    Boster A; Hreha S; Berger JR; Bao F; Penmesta R; Tselis A; Endress C; Zak I; Perumal J; Caon C; Vazquez J; Tyler KL; Racke MK; Millis S; Khan O
    Arch Neurol; 2009 May; 66(5):593-9. PubMed ID: 19433659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progressive multifocal leukoencephalopathy without overt immunosuppression.
    Jain V; Branstetter H; Savaram S; Vasquez M; Swords G; Aghili-Mehrizi S; Rees J; Rivera-Zengotita M; Montalvo M; Chuquilin M; Patterson A; Rempe T
    Medicine (Baltimore); 2023 Sep; 102(39):e35265. PubMed ID: 37773871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disease-modifying therapies and progressive multifocal leukoencephalopathy in multiple sclerosis: A systematic review and meta-analysis.
    Sriwastava S; Kataria S; Srivastava S; Kazemlou S; Gao S; Wen S; Saber H; Tripathi R; Sheikh Z; Peterson S; Gwinn R; Bernitsas E
    J Neuroimmunol; 2021 Nov; 360():577721. PubMed ID: 34547511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching patients at high risk of PML from natalizumab to another disease-modifying therapy.
    Giovannoni G; Marta M; Davis A; Turner B; Gnanapavan S; Schmierer K
    Pract Neurol; 2016 Oct; 16(5):389-93. PubMed ID: 27114560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Classifying PML risk with disease modifying therapies.
    Berger JR
    Mult Scler Relat Disord; 2017 Feb; 12():59-63. PubMed ID: 28283109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progressive multifocal leukoencephalopathy in a patient with mediastinal teratoma: a case report.
    Wang W; Yang H; Piao Y; Quan M; Guo D
    BMC Neurol; 2022 Jan; 22(1):40. PubMed ID: 35086492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early reduction of the splicing factor2/alternative splicing factor: a cellular inhibitor of the JC polyomavirus in natalizumab-treated MS patients long before developing progressive multifocal leukoencephalopathy.
    Piu C; Ibba G; Bertoli D; Capra R; Uleri E; Serra C; Imberti L; Dolei A
    J Neurovirol; 2020 Feb; 26(1):133-137. PubMed ID: 31468472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progressive Multifocal Leukoencephalopathy in a Patient With Progressive Multiple Sclerosis Treated With Ocrelizumab Monotherapy.
    Patel A; Sul J; Gordon ML; Steinklein J; Sanguinetti S; Pramanik B; Purohit D; Haroutunian V; Williamson A; Koralnik I; Harel A
    JAMA Neurol; 2021 Jun; 78(6):736-740. PubMed ID: 33724354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.